• Explore /
  • Poster
  • / Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.

Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.

Abstract Poster

Authors

null

Eve Maubec

AP-HP Dermatology Department, Hôpital Avicenne, Université Paris 13, Bobigny, France

Eve Maubec , Marouane Boubaya , Peter Petrow , Nicole Basset-Seguin , Jean Jacques Grob , Brigitte Dréno , Marie Beylot-Barry , Isabelle Scheer-Senyarich , Sabine Helfen , Marie Thérèse Leccia , Andreea Raluca Stefan , Philippe Saiag , Julie De Quatrebarbes , Nicolas Meyer , Lydia Deschamps , Céline Alloux , Isabelle Lopez , Soufian Cherbal , Annick Tibi , Vincent Lévy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02883556

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9547)

DOI

10.1200/JCO.2019.37.15_suppl.9547

Abstract #

9547

Poster Bd #

118

Abstract Disclosures

Similar Posters

First Author: Eve Maubec

First Author: Eve Maubec

First Author: Rodrigo Ramella Munhoz

First Author: Dong-Sheng Zhang